KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (Weighted Average): 2017-2024

Historic Shares Outstanding (Weighted Average) for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $91.2 million.

  • Aquestive Therapeutics' Shares Outstanding (Weighted Average) rose 9.51% to $99.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.7 million, marking a year-over-year increase of 9.51%. This contributed to the annual value of $91.2 million for FY2024, which is 36.56% up from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Shares Outstanding (Weighted Average) is $91.2 million, which was up 36.56% from $66.8 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Shares Outstanding (Weighted Average) registered a high of $91.2 million during FY2024, and its lowest value of $33.6 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $70.7 million, with a median of $66.8 million in 2023.
  • Data for Aquestive Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 36.56% (in 2024) over the last 5 years.
  • Aquestive Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $33.6 million in 2020, then grew by 19.47% to $40.2 million in 2021, then skyrocketed by 34.84% to $54.2 million in 2022, then increased by 23.29% to $66.8 million in 2023, then soared by 36.56% to $91.2 million in 2024.